{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:22Z","timestamp":1793598202677,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Severance Hospital"},{"name":"Sung-Kil Lim Research Award"},{"DOI":"10.13039\/100019265","name":"Yuhan Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019265","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-04017-x","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:08:10Z","timestamp":1746623290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Minyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukchul","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongin","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungjin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Heui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Wan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-2854","authenticated-orcid":false,"given":"Bong-Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"5","key":"4017_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.4093\/dmj.2020.0115","volume":"44","author":"SW Jeong","year":"2020","unstructured":"Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44(5):640\u201357.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"4017_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","volume":"76","author":"M Kokkorakis","year":"2024","unstructured":"Kokkorakis M, Muzurovic E, Volcansek S, Chakhtoura M, Hill MA, Mikhailidis DP, Mantzoros CS. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies. Pharmacol Rev. 2024;76(3):454\u201399.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"4017_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"key":"4017_CR4","doi-asserted-by":"crossref","unstructured":"Oh R, Kim S, Cho SH, Kim J, Lee YB, Jin SM, Hur KY, Kim G, Kim JH: Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality. Diabetes Metab J 2025;49(1):80\u201391.","DOI":"10.4093\/dmj.2024.0042"},{"issue":"3","key":"4017_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/hep.24127","volume":"53","author":"EM Brunt","year":"2011","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53(3):810\u201320.","journal-title":"Hepatology"},{"issue":"3","key":"4017_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4093\/dmj.2020.0010","volume":"44","author":"BW Lee","year":"2020","unstructured":"Lee BW, Lee YH, Park CY, Rhee EJ, Lee WY, Kim NH, Choi KM, Park KG, Choi YK, Cha BS, et al. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J. 2020;44(3):382\u2013401.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"4017_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"VWS Wong","year":"2024","unstructured":"Wong VWS, Ratziu V, Bugianesi E, Francque S, Zelber-Sagi S, Valenti L, Roden M, Schick F, Yki-J\u00e4rvinen H, Gastaldelli A, et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"6","key":"4017_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/dom.14687","volume":"24","author":"JD Spence","year":"2022","unstructured":"Spence JD, Viscoli C, Kernan WN, Young LH, Furie K, DeFronzo R, Abdul-Ghani M, Dandona P, Inzucchi SE. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes Obes Metab. 2022;24(6):1150\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"4017_CR9","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/ijms23063107","volume":"23","author":"T Androutsakos","year":"2022","unstructured":"Androutsakos T, Nasiri-Ansari N, Bakasis AD, Kyrou I, Efstathopoulos E, Randeva HS, Kassi E. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int J Mol Sci. 2022;23(6):3107.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4017_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/hep.20012","volume":"39","author":"K Promrat","year":"2004","unstructured":"Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39(1):188\u201396.","journal-title":"Hepatology"},{"issue":"6","key":"4017_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.4093\/dmj.2023.0359","volume":"48","author":"JY Kim","year":"2024","unstructured":"Kim JY, Lee J, Kim SG, Kim NH. Recent Glycemia Is a Major Determinant of \u03b2-Cell Function in Type 2 Diabetes Mellitus. Diabetes Metab J. 2024;48(6):1135\u201346.","journal-title":"Diabetes Metab J"},{"issue":"7","key":"4017_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Digest Liver Dis. 2010;42(7):503\u20138.","journal-title":"Digest Liver Dis"},{"key":"4017_CR13","doi-asserted-by":"crossref","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and FibroTest. Hepatology. 2007;46(1):32\u201336.","DOI":"10.1002\/hep.21669"},{"issue":"3","key":"4017_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu YN, Billin AN, Damgaard LH, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol. 2022;77(3):607\u201318.","journal-title":"J Hepatol"},{"issue":"1","key":"4017_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12916-022-02288-2","volume":"20","author":"Y Cho","year":"2022","unstructured":"Cho Y, Rhee H, Kim YE, Lee M, Lee BW, Kang ES, Cha BS, Choi JY, Lee YH. Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). Bmc Med. 2022;20(1):93.","journal-title":"Bmc Med"},{"issue":"5","key":"4017_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/RMR.0000000000000177","volume":"27","author":"S Hoodeshenas","year":"2018","unstructured":"Hoodeshenas S, Yin M, Venkatesh SK. Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging. 2018;27(5):319\u201333.","journal-title":"Top Magn Reson Imaging"},{"issue":"6","key":"4017_CR17","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"G Marchesini","year":"2016","unstructured":"Marchesini G, Day CP, Dufour JF, Canbay A, Nobili V, Ratziu V, Tilg H, Roden M, Gastaldelli A, Yki-J\u00e4rvinen H, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"7","key":"4017_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1136\/gut.2005.085399","volume":"55","author":"F Marra","year":"2006","unstructured":"Marra F. Thiazolidinediones and hepatic fibrosis: don\u2019t wait too long. Gut. 2006;55(7):917\u20139.","journal-title":"Gut"},{"key":"4017_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.615409","volume":"12","author":"J Lian","year":"2021","unstructured":"Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:615409.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"4017_CR20","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.dld.2024.04.031","volume":"56","author":"XD Wei","year":"2024","unstructured":"Wei XD, Qi S, Wei XH, Qiu LX, Du XF, Liu YL, Xu HF, Zhao JH, Chen ST, Zhang J. Inflammation activity affects liver stiffness measurement by magnetic resonance elastography in MASLD. Digest Liver Dis. 2024;56(10):1715\u201320.","journal-title":"Digest Liver Dis"},{"issue":"11","key":"4017_CR21","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2337\/dc15-2688","volume":"39","author":"G Daniele","year":"2016","unstructured":"Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care. 2016;39(11):2036\u201341.","journal-title":"Diabetes Care"},{"issue":"6","key":"4017_CR22","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/medicina59061136","volume":"59","author":"IC Bica","year":"2023","unstructured":"Bica IC, Stoica RA, Salmen T, Janez A, Volcansek S, Popovic D, Muzurovic E, Rizzo M, Stoian AP. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials. Medicina (Kaunas). 2023;59(6):1136.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"4017_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/hep4.1696","volume":"6","author":"H Takahashi","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, Nonaka M, Hyogo H, Fujii H, Nakajima T, Imajo K, Tanaka K, Kubotsu Y, et al. Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. Hepatol Commun. 2022;6(1):120\u201332.","journal-title":"Hepatol Commun"},{"issue":"3","key":"4017_CR24","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/hep.31806","volume":"74","author":"AS Alexopoulos","year":"2021","unstructured":"Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, Piercy DL, Seymour KA, Sudan R, Portenier DD, et al. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021;74(3):1220\u201333.","journal-title":"Hepatology"},{"issue":"3","key":"4017_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","volume":"27","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010;27(3):309\u201317.","journal-title":"Diabet Med"},{"key":"4017_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117090","volume":"240","author":"H Yaribeygi","year":"2020","unstructured":"Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review. Life Sci. 2020;240:117090.","journal-title":"Life Sci"},{"issue":"3","key":"4017_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/cld.1183","volume":"19","author":"CL Hanlon","year":"2022","unstructured":"Hanlon CL, Yuan L. Nonalcoholic Fatty Liver Disease: The Role of Visceral Adipose Tissue. Clin Liver Dis (Hoboken). 2022;19(3):106\u201310.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"6","key":"4017_CR28","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2337\/dc08-2280","volume":"32","author":"SA Porter","year":"2009","unstructured":"Porter SA, Massaro JM, Hoffmann U, Vasan RS, O\u2019Donnel CJ, Fox CS. Abdominal subcutaneous adipose tissue: a protective fat depot? Diabetes Care. 2009;32(6):1068\u201375.","journal-title":"Diabetes Care"},{"key":"4017_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/489187","volume":"2013","author":"P Patel","year":"2013","unstructured":"Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes. 2013;2013:489187.","journal-title":"J Obes"},{"key":"4017_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155612","volume":"145","author":"HJ Chun","year":"2023","unstructured":"Chun HJ, Kim ER, Lee M, Choi DH, Kim SH, Shin E, Kim JH, Cho JW, Han DH, Cha BS, et al. Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis. Metabolism. 2023;145:155612.","journal-title":"Metabolism"},{"issue":"9","key":"4017_CR31","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1002\/hep4.1993","volume":"6","author":"M Yoneda","year":"2022","unstructured":"Yoneda M, Kobayashi T, Honda Y, Ogawa Y, Kessoku T, Imajo K, Nogami A, Taguri M, Kirikoshi H, Saito S, et al. Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. Hepatol Commun. 2022;6(9):2273\u201385.","journal-title":"Hepatol Commun"},{"issue":"5","key":"4017_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1183\/09031936.00136408","volume":"32","author":"A Hackshaw","year":"2008","unstructured":"Hackshaw A. Small studies: strengths and limitations. Eur Respir J. 2008;32(5):1141\u20133.","journal-title":"Eur Respir J"},{"issue":"6","key":"4017_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4097\/kjae.2017.70.6.601","volume":"70","author":"J In","year":"2017","unstructured":"In J. Introduction of a pilot study. Korean J Anesthesiol. 2017;70(6):601\u20135.","journal-title":"Korean J Anesthesiol"},{"issue":"18","key":"4017_CR34","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","volume":"362","author":"AJ Sanyal","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675\u201385.","journal-title":"N Engl J Med"},{"issue":"22","key":"4017_CR35","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New Engl J Med. 2006;355(22):2297\u2013307.","journal-title":"New Engl J Med"},{"issue":"2","key":"4017_CR36","first-page":"272","volume":"14","author":"S Cernea","year":"2024","unstructured":"Cernea S. NAFLD Fibrosis Progression and Type 2 Diabetes: The Hepatic-Metabolic Interplay. Life (Basel). 2024;14(2):272.","journal-title":"Life (Basel)"},{"issue":"3","key":"4017_CR37","first-page":"E829","volume":"292","author":"L Juurinen","year":"2007","unstructured":"Juurinen L, Tiikkainen M, H\u00e4kkinen AM, Hakkarainen A, Yki-J\u00e4rvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol-Endoc M. 2007;292(3):E829\u201335.","journal-title":"Am J Physiol-Endoc M"},{"issue":"1","key":"4017_CR38","doi-asserted-by":"publisher","first-page":"5389","DOI":"10.1038\/s41598-019-41854-2","volume":"9","author":"F Alam","year":"2019","unstructured":"Alam F, Islam MA, Mohamed M, Ahmad I, Kamal MA, Donnelly R, Idris I, Gan SH. Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Sci Rep. 2019;9(1):5389.","journal-title":"Sci Rep"},{"issue":"8","key":"4017_CR39","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.2337\/dc19-2419","volume":"43","author":"S Gan","year":"2020","unstructured":"Gan S, Dawed AY, Donnelly LA, Nair ATN, Palmer CNA, Mohan V, Pearson ER. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2020;43(8):1948\u201357.","journal-title":"Diabetes Care"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04017-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04017-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T13:08:14Z","timestamp":1746623294000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04017-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4017"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04017-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent and the Ethics Committee of the Yonsei University College of Medicine approved this study (4-2018-0655), which conforms to the ethical principles of the 1975 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.L. has received lecture honoraria from JW Pharmaceutical Corporation, Boryung Corporation, Eli Lilly and Company, Merck Sharp & Dohme, HK inno.N, Servier Korea, Handok Inc., Daewoong Pharmaceutical, KUKJE PHARM CO.,LTD, and GC Biopharma Corporation. All other authors have no conflicts to disclose; no other relationships or activities that could appear to have influenced the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}